Tacere secures funding to resume study of TT-033i, stabilize operations

By Lisa Kerner

Charlotte, N.C., Oct. 12 - Tacere Therapeutics, Inc. secured an undisclosed amount of seed financing from Hokkaido Venture Capital, according to a company news release.

The company said the funding stabilized its operations and allowed preclinical development of TT-033i, its lead candidate for the treatment of hepatitis C, to resume.

"The company will also capitalize on its extensive knowledge of hepatitis C to advance a number of novel small molecule compounds for the treatment of this viral disease," president and chief executive officer Sara Cunningham Hall said in the release.

Tacere is a San Jose, Calif., biotechnology company that develops therapeutics for the treatment of infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.